Serum periostin has been proposed as a surrogate biomarker of Th2 inflammatory response in patients with asthma, but its predictive role in hospitalized patients with COPD has not been evaluated.
The aim of the present observational prospective cohort study was to evaluate the possible role of serum periostin as predictor of outcome in COPD patients hospitalized for AECOPD.
Serum periostin was measured on admission and at discharge in patients admitted to the hospital for a COPD exacerbation. Patients were followed-up for 1 year for future exacerbations, hospitalizations and mortality.
155 consecutive patients admitted to the hospital for AECOPD were included to the study. Periostin levels on admission were elevated compared to discharge [34.7 (25.2–52.2) vs. 25.9 (17.4–41.0) ng/mL, p = 0.003], but serum periostin levels did not differ between patients with or without prolonged hospitalization, or those who required non-invasive ventilation, intubation, or died during hospitalization. Frequent exacerbators had higher serum periostin levels at the time of discharge compared to non-frequent exacerbators [37.9 (26.6, 64.5) vs. 23.9 (16.2, 37.9), p < 0.001]. Periostin levels above the median value (25 ng/mL) were not related to the time of next exacerbation, time of next COPD hospitalization, (p = 0.858) or time to death.
The role of serum periostin levels as a predictive biomarker of future risk in hospitalized patients with COPD is of limited value.